Toggle Main Menu Toggle Search

Open Access padlockePrints

Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone

Lookup NU author(s): James Talks

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

center dot PURPOSE: To evaluate the efficacy and safety of photody, namic therapy (PDT) with verteporfin combined with intravitreal triamcinolone (TA) in retinal angiomatous proliferation (RAP). center dot DESIGN: Retrospective, consecutive, noncomparative case series. center dot METHODS: Patients newly diagnosed with RAP underwent indocyanine green angiography (ICGA)-guided PDT with verteporfin, immediately followed by intra-vitreal TA. Complete ocular examination, fluorescein angiography (FA), ICGA, and optical coherence tomog, raphy (OCT) were performed at baseline and follow,up visits every three months. center dot RESULTS: Seventeen eyes of seventeen patients underwent this simultaneous combined treatment. All patients had 12 months of follow-up. Complete resolution of angiographic leakage was achieved in 83% at 12 months. Visual acuity improved in 35%, and was stable in 47%. Eleven patients developed recurrent leakage after six to 12 months, which settled completely after repeat combined treatment. center dot CONCLUSIONS: This simultaneous combined treatment in patients with RAP was effective in reducing or eliminating retinal edema, regression of neovascularization, and stabilizing or improving visual acuity.


Publication metadata

Author(s): van de Moere A, Kak R, Sandhu SS, Talks SJ

Publication type: Article

Publication status: Published

Journal: American Journal of Ophthalmology

Year: 2007

Volume: 143

Issue: 4

Pages: 701-704

ISSN (print): 0002-9394

ISSN (electronic): 1879-1891

Publisher: Elsevier Inc.

URL: http://dx.doi.org/10.1016/j.ajo.2006.10.045

DOI: 10.1016/j.ajo.2006.10.045


Altmetrics

Altmetrics provided by Altmetric


Share